Kyverna Therapeutics, Inc. (KYTX)

Market Cap	146.78M
Revenue (ttm)	n/a
Net Income (ttm)	-110.66M
Shares Out	43.17M
EPS (ttm)	-3.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	153,497
Open	3.375
Previous Close	3.340
Day's Range	3.320 - 3.500
52-Week Range	3.220 - 30.600
Beta	n/a
Analysts	Buy
Price Target	23.20 (+582.35%)
Earnings Date	Feb 12, 2025

About KYTX

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 8, 2024
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: KYTX
• Website: https://kyvernatx.com

Analyst Forecast

According to 5 analysts, the average rating for KYTX stock is "Buy." The 12-month stock price forecast is $23.2, which is an increase of 582.35% from the latest price.

Price Target

$23.2

(582.35% upside)

Analyst Consensus: Buy